Simplified, end-to-end solution will help biopharmaceutical clients provide compassionate access to their treatments for patientsLondon, January 26, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched an expanded Managed Access Programs service. PAREXEL now offers end-to-end expertise for the design, development, and delivery of managed access programs to help biopharmaceutical companies provide access to investigational medical products for patients in need.Managed Access Programs provide use of an investigational medical…

Source: RealWire

Leave a Reply